Department of Haematological Medicine, King's College Hospital, London, United Kingdom.
Department of Haematological Medicine, Cancer Studies Division, Rayne Institute, King's College, London, United Kingdom.
Blood Adv. 2018 Jan 4;2(1):36-48. doi: 10.1182/bloodadvances.2017008110. eCollection 2018 Jan 9.
Biallelic germline mutations in (regulator of telomere elongation helicase 1) result in pathologic telomere erosion and cause dyskeratosis congenita. However, the role of mutations in other bone marrow failure (BMF) syndromes and myeloid neoplasms, and the contribution of monoallelic mutations to disease development are not well defined. We screened 516 patients for germline mutations in telomere-associated genes by next-generation sequencing in 2 independent cohorts; one constituting unselected patients with idiopathic BMF, unexplained cytopenia, or myeloid neoplasms (n = 457) and a second cohort comprising selected patients on the basis of the suspicion of constitutional/familial BMF (n = 59). Twenty-three variants were identified in 27 unrelated patients from both cohorts: 7 variants were likely pathogenic, 13 were of uncertain significance, and 3 were likely benign. Likely pathogenic variants were identified in 9 unrelated patients (7 heterozygous and 2 biallelic). Most patients were suspected to have constitutional BMF, which included aplastic anemia (AA), unexplained cytopenia, hypoplastic myelodysplastic syndrome, and macrocytosis with hypocellular bone marrow. In the other 18 patients, variants were likely benign or of uncertain significance. Telomeres were short in 21 patients (78%), and 3' telomeric overhangs were significantly eroded in 4. In summary, heterozygous variants were associated with marrow failure, and telomere length measurement alone may not identify patients with telomere dysfunction carrying variants. Pathogenicity assessment of heterozygous variants relied on a combination of clinical, computational, and functional data required to avoid misinterpretation of common variants.
双等位基因种系突变 (端粒延长解旋酶 1 的调节因子)导致病理性端粒侵蚀,并导致先天性角化不良。然而, 突变在其他骨髓衰竭(BMF)综合征和髓系肿瘤中的作用,以及单等位基因 突变对疾病发展的贡献尚不清楚。我们通过下一代测序在 2 个独立队列中筛选了 516 名患者的端粒相关基因的种系突变;一个队列由特发性 BMF、不明原因血细胞减少或髓系肿瘤的未选择患者组成(n = 457),另一个队列由基于怀疑存在先天/家族性 BMF 的选择患者组成(n = 59)。在两个队列的 27 名无关患者中发现了 23 个 变异:7 个变异可能是致病性的,13 个是意义不明的,3 个可能是良性的。9 名无关患者(7 名杂合子和 2 名纯合子)中发现了可能致病性的 变异。大多数患者疑似患有先天 BMF,包括再生障碍性贫血(AA)、不明原因血细胞减少、低增生性骨髓增生异常综合征和巨红细胞症伴骨髓细胞减少。在其他 18 名患者中, 变异可能是良性的或意义不明的。21 名患者(78%)的端粒较短,4 名患者的 3'端粒突出明显侵蚀。总之,杂合子 变异与骨髓衰竭相关,单独测量端粒长度可能无法识别携带 变异的端粒功能障碍患者。杂合子 变异的致病性评估依赖于临床、计算和功能数据的组合,以避免对常见变异的错误解释。